XML 37 R27.htm IDEA: XBRL DOCUMENT v3.19.1
Stockholders' Equity (Deficit) (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Feb. 25, 2019
Jan. 02, 2019
Jan. 02, 2017
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Dec. 31, 2016
Dec. 31, 2017
Stock options outstanding       3,947,866   3,846,299   3,566,299
Stock options outstanding weighted average exercise price       $ 1.36   $ 1.36   $ 1.33
Stock options intrinsic value       $ 2,546,041   $ 2,444,474    
Number of stock options granted       101,567   280,000    
Stock option weighted average exercise price per share       $ 1.00   $ 1.75    
Employee service share-based compensation, nonvested awards, compensation cost not yet recognized       $ 871,485        
Employee service share-based compensation, nonvested awards, compensation cost not yet recognized, period for recognition       3 years 2 months 5 days        
Stock options granted, term       7 years 2 months 12 days   8 years 18 days    
Number of stock options vested       327,551   972,651    
Class of warrant or right, outstanding       3,826,658   3,826,658   3,826,658
Class of warrant or right, outstanding, weighted average exercise price       $ 1.05   $ 1.05   $ 1.05
Class of warrant or right, outstanding, intrinsic value           $ 3,633,335    
Series B Preferred Stock [Member] | Private Placement [Member]                
Class of warrant or right, number of securities called by warrants or rights       423,291        
Class of warrant or right, exercise price of warrants or rights             $ 1.25  
Class of warrant or right, expiration period       5 years     5 years  
Protagenic Therapeutics Inc [Member]                
Debt instrument, face amount       $ 665,000        
Accrued interest       $ 35,000        
Protagenic Therapeutics Inc [Member] | Predecessor Warrants [Member]                
Class of warrant or right, number of securities called by warrants or rights       295,945        
Class of warrant or right, exercise price of warrants or rights       $ 1.25        
Protagenic Therapeutics Inc [Member] | Placement Agent Warrants [Member]                
Class of warrant or right, number of securities called by warrants or rights       127,346        
Class of warrant or right, exercise price of warrants or rights       $ 1.25        
Protagenic Therapeutics Inc [Member] | Series B Preferred Stock [Member] | Private Placement [Member]                
Class of warrant or right, number of securities called by warrants or rights       3,403,367        
Class of warrant or right, exercise price of warrants or rights       $ 1.05        
Employees [Member]                
Compensation expense       $ 335,562        
Employee service share-based compensation, nonvested awards, compensation cost not yet recognized       409,055        
Non-Employees [Member]                
Compensation expense       115,579        
Employee service share-based compensation, nonvested awards, compensation cost not yet recognized       $ 462,430        
Stock Option [Member]                
Number of stock options granted       101,567 280,000      
Stock option weighted average exercise price per share       $ 1.00 $ 1.25      
Compensation expense       $ 451,141 $ 344,647      
Stock Options [Member]                
Number of stock options vested 59,900              
Stock options fair value $ 199,807              
Stock Options [Member] | Vest bi-Weekly Over Two Months [Member]                
Number of stock options vested 41,667              
The 2016 Plan [Member]                
Number of additional shares grants for issuance   564,378 564,378          
Number of shares available for grant   1,128,756 1,128,756 3,739,867        
Share-based payment award, expiration period       10 years